What is the price of ALNY stock today?
Alnylam Pharmaceuticals, Inc. (traded on the NASDAQ under the ticker ALNY) trades at a live market price of approximately $216.07 per share. As a pioneer in RNA interference therapeutics, its stock price responds dynamically to commercial revenue growth from approved RNAi products, clinical trial advancements in rare and prevalent diseases, collaboration milestones, and broader biotechnology sector sentiment.
Related FAQs
Evaluating the stock volatility and market risk profile of Ambarella, Inc.—a fabless semiconductor company specializing in low-power video compression and computer vision processors—reveals an exceptionally high-beta, volatile profile.
Bill Clinton did not pay off the total U.S. national debt. However, his administration is noted for being the only one between 1970 and 2018 to pay down the debt held by the public.
Alnylam Pharmaceuticals has faced intense biopharmaceutical industry debates and intellectual property patent disputes regarding its pioneering RNA interference therapeutic technologies.
Dallas Cowboys owner and prominent wildcatter Jerry Jones has invested more than 1.1 billion US dollars into Comstock Resources, a major natural gas producer operating heavily across North America.
Assessing Alnylam Pharmaceuticals as an equity investment reveals a cutting-edge biotechnology pioneer specializing in RNA interference therapies designed to treat rare and prevalent genetic diseases.
Pfizer’s legendary cholesterol-lowering medication Lipitor (atorvastatin) holds the historical crown as the most lucrative pharmaceutical product ever commercialized, generating tens of billions of dollars in cumulative global revenue throughout its ...
ALS Limited (operating globally as ALS Global) employs approximately 18,000 to 19,000 people across its extensive testing, inspection, and certification operations.
The global biopharmaceutical and innovative medicine landscape is anchored by massive research-driven enterprises that generate tens of billions in annual revenue through advanced drug development.
Novo Nordisk, a major Danish multinational pharmaceutical enterprise headquartered in Bagsværd, Denmark, is the creator and manufacturer of Ozempic (semaglutide).
Determining whether Albemarle warrants a strong buy recommendation depends on shifting consensus ratings from chemical and mining equity analysts tracking commodity cycles.
AltaGas Ltd. is performing exceptionally well, underpinned by robust operational results across its utility and midstream infrastructure segments.
Determining whether Alnylam Pharmaceuticals represents a buy or sell recommendation involves reviewing consensus equity research ratings from biotechnology and healthcare analysts.
Alnylam Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, United States. Situated in one of the world's premier clusters for biotechnology and life sciences research, the company's corporate campus is located in Kendall Square.
Alnylam Pharmaceuticals maintains a highly centralized and concentrated operational footprint within the United States, with the vast majority of its core activities—including research, development, and corporate management—situated in Cambridge, Mas...